Specialty Healthcare Operator Commons Clinic Raises $26 Million
Funds will support an expansion of its specialty medical clinic with the launch of Wholebody by Commons Clinic, a multi-specialty suite connecting all of the organization's advanced preventative care offerings.
'Specialty healthcare too often begins after prevention fails. Patients lack timely access to specialized clinical expertise, leaving conditions to worsen over time before they receive treatment,' said Nick Aubin, chief executive and co-founder of Commons Clinic, in a statement.
Board-certified cardiologist Dr. Jenica Ortega will lead the Wholebody program, with a specific focus on building its cardiac, metabolic, bariatric and women's health service lines. Additionally, Brad Hively, the former chief executive of The Oncology Institute, recently joined Commons' board.
Information for this article was sourced from Common Clinics.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Axios
15 minutes ago
- Axios
Bloom Nutrition enters prebiotic soda category
Austin-based Bloom Nutrition is expanding into the growing prebiotic soda market with Bloom Pop, debuting at Walmart. Why it matters: The company aims to capitalize on skyrocketing consumer demand for gut-friendly, low-sugar drinks — and compete in the increasingly crowded better-for-you soda category now worth over $1 billion. A growing number of wellness brands, including Austin-based Poppi and national startups like Olipop, are seeking to disrupt the $110 billion soft drink market. The big picture: Founded in 2019, Bloom first made its name with a greens and superfoods powder, which it claims supports health, digestion and energy. The company's push into prebiotic sodas follows the success of its sparkling energy drink, launched last year. Bloom says it sold more than 35 million cans of its energy drink in its first year. What they're saying:"Launching a better-for-you soda was a natural evolution for Bloom," Bloom co-founder CEO Greg LaVecchia said in a statement. "We've never shied away from competitive categories, because that's where the real opportunities live."
Associated Press
22 minutes ago
- Associated Press
Biotech Breakthroughs in Anti-Aging: Decoding the Hallmarks of Aging and the Longevity Code
The Hong Kong Society of Cosmetic Chemists (HKSCC) Invites Swiss Biotech Expert to unveil scientific truths behind aging HONG KONG SAR - Media OutReach Newswire - 16 July 2025 - From the popularity of anti-aging supplements and aesthetic treatments to Silicon Valley billionaires' pursuit of immortality, the global wave of anti-aging is gaining momentum, and Hong Kong is no exception. Questions like 'How to stay young?', 'Is NMN really effective?' and 'At what age should you start anti-aging care?' have become part of everyday conversation. While many are eager to delay the signs of aging, few truly understand the science behind it. Dr Fred Zülli (second from right), Founder and Business Development Director of Mibelle Biochemistry, Francis Kwan (second from left), President of HKSCC, Cirrus Chu (first from left), Sales Director of TPMC International Limited and Fanny Cheung (first from right), Director of NF Essential Limited attended the anti-aging seminar. From Hallmarks of Aging to Scientific Action: Effective Solutions Revealed To address this knowledge gap, Dr. Fred Zülli, Founder and Business Development Director of Swiss-based biotech company Mibelle Biochemistry, was specially invited to Hong Kong to co-host a seminar with the Hong Kong Society of Cosmetic Chemists. The seminar provided an in-depth look at the latest advancements in Swiss anti-aging research, starting with the 12 'Hallmarks of Aging' theory published in the journal Cell. Dr. Zülli explained how Swiss biotechnology is strategically targeting these biological mechanisms of aging and translating scientific breakthroughs into practical applications in skincare and aesthetic medicine, making age-defying solutions a scientific reality rather than a distant ideal. During the seminar, Dr. Zülli also revealed several truly effective, science-backed methods to combat aging. Next-Gen Skincare Science: Goji Stem Cell Extract with Dual Action Power for Repair Exosomes have rapidly emerged as one of the most promising technologies in the skincare industry. According to market data, the global exosome market was valued at over US$140 million in 2023 and is projected to expand at 28% CAGR by 2030. In the U.S., Google searches for 'exosomes' surged 17% in one year, evidence of rising consumer interest. Dr. Fred Zülli explains that exosomes are tiny vesicles that are released by cells into the extracellular space, rich in proteins, lipids, and nucleic acids. They can be derived from human, animals or plants cells, including plant stem cells, and reconstructed using liposome technology. These 'cellular messengers' play key roles in intercellular communication, immune modulation, and drug delivery. When used in skincare or microneedling treatments, they accelerate wound healing, enhance skin regeneration, and deliver deeper, faster, and safer results. Exosomes offer dual benefits: they strengthen the skin barrier while activating deeper cellular repair, improving overall skin quality, reducing fine lines, and restoring firmness for true inside-out anti-aging effects. Clinically Proven Plant Stem Cells Go Beyond Surface-Level Skincare Swiss researchers at Mibelle have developed the PhytoCellTec™ Exosomes technology, using natural Goji Stem Cell Extract to stimulate exosome production. This powerful natural ingredient demonstrates 'dual action', promoting keratinocyte differentiation and the expression of epidermal growth and antioxidant-related genes to reinforce the skin's outer barrier. Meanwhile, it reactivates mesenchymal stem cells (MSCs), boosting collagen synthesis and cellular vitality to enhance skin elasticity and density. Clinical studies show that a cream containing just 0.4% of Goji Stem Cell Extract significantly reduces fine lines and wrinkles after 56 days. Results can be seen in just 28 days with improved skin density and facial contour, and even firmness and lifting effects when applied to the breast area, showcasing its applications well beyond facial skincare. Exosomes in Daily Skincare and Medical Aesthetics With proven regenerative and wound-healing properties, exosomes are emerging as a viable alternative to stem cell therapies. As non-living biological elements, they are more stable and easier to handle. Exosome-based serums are particularly effective when used with microneedling, enabling deep skin repair and faster healing. Plant-derived exosomes have been shown to be bioavailable to mammalian cells and exhibit anti-inflammatory, antioxidant, anti-tumour, and skin-repairing benefits. Recent studies confirm their ability to combat skin aging, reinforcing their growing role in both cosmetic dermatology and everyday skincare. As this technology evolves, it promises a new era of personalized, science-backed beauty. Dual Stem Cell Formula: 'Swiss StemGlow Jelly' Nourishes Youthful Skin from Within; The brand 'LAB 91" Unveils Advanced Microneedle Skincare Powered by Deep Cellular Repair The Swiss StemGlow Jelly is an edible functional jelly formulated with dual stem cell active ingredients, Swiss apple stem cells and grape stem cells. These ingredients are renowned for enhancing cellular vitality, delivering antioxidant protection, and shielding the skin from UV damage. Meanwhile, LAB 91, a Swiss-made brand, specializes in microneedle skincare solutions. Its signature innovation, the Dual Plant Stem Cell Exosome Complex, combines rare Swiss apple stem cells with goji stem cells to deeply penetrate the skin and trigger cellular repair. Proven results include improved skin elasticity, lifted facial contours, and visibly diminished wrinkles. The brand offers a range of ampoule serums tailored to various skin concerns, including anti-aging, brightening and intensive repair. Together, the edible jelly and topical microneedle treatments deliver synergistic, cell-level rejuvenation from the inside out. Hashtag: #ESDLife The issuer is solely responsible for the content of this announcement. About ESDlife ESDlife, a joint venture of CK Hutchison (formerly Hutchison Whampoa) and Hewlett-Packard HK SAR, operates the award-winning website ( ) and establishes it as one of the most popular and trusted online lifestyle media in Hong Kong. The online platform of ESDlife is furnished with a wide range of lifestyles information under the categories of Wedding, Family and Health. In addition to the prominent No. 1 position of its Wedding Channel in Hong Kong, an e-commerce platform is provided to consumers by offering medical check-up ordering services. ESDlife also delivers integrated marketing and digital solutions to diversified corporate clients.
Yahoo
an hour ago
- Yahoo
Henry Schein's Quarterly Earnings Preview: What You Need to Know
Melville, New York-based Henry Schein, Inc. (HSIC) provides healthcare products and services to office-based dental and medical practitioners, as well as alternative sites of care worldwide. With a market capitalization of $8.6 billion, the company operates through four segments: Global Distribution and Value-Added Services, Global Specialty Products, and Global Technology. HSIC is all geared up to report its Q2 2025 results on Tuesday, August 5. Before this event, analysts project that the company will report an adjusted EPS of $1.19, down 3.3% from $1.23 in the year-ago quarter. The company has surpassed or matched Wall Street's bottom-line estimates in each of the last four quarters, which is impressive. Dear Nvidia Stock Fans, Mark Your Calendars for July 16 Seeking Passive Income? This 'Strong Buy' Dividend Stock Yields 8.6%. How to Buy Tesla for a 13% Discount, or Achieve a 26% Annual Return Tired of missing midday reversals? The FREE Barchart Brief newsletter keeps you in the know. Sign up now! For fiscal 2025, analysts expect HSIC to report an adjusted EPS of $4.86, representing a 2.5% year-over-year increase from $4.74 in fiscal 2024. Moreover, in fiscal 2026, the company's adjusted EPS is expected to increase 8.6% year-over-year to $5.28. HSIC stock has grown 7.3% over the past 52 weeks, lagging behind the S&P 500 Index's ($SPX) 10.9% gain but outperforming the Health Care Select Sector SPDR Fund's (XLV) 10.3% decline over the same time frame. HSIC stock rose 2% following the release of its Q1 2025 results on May 5. The company's net sales declined marginally year-over-year to $3.2 billion, missing the consensus estimate. Meanwhile, its adjusted EPS grew 4.5% from the prior-year quarter to $1.15, surpassing analysts' estimate by 3.6%. Analysts are moderately optimistic about HISC's stock, with an overall "Moderate Buy" rating. Among 14 analysts covering the stock, five recommend "Strong Buy," eight advise 'Hold,' and one suggests 'Strong Sell.' The mean price target of $77 indicates a 9% potential upside from HSIC's current price levels. On the date of publication, Kritika Sarmah did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
